The adverse event profile of brivaracetam: A meta-analysis of randomized controlled trials
- 1 February 2017
- journal article
- research article
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 45, 7-16
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: A systematic review and meta-analysisEpilepsia, 2011
- Adjunctive brivaracetam for refractory partial-onset seizuresNeurology, 2010
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009
- The global burden and stigma of epilepsyEpilepsy & Behavior, 2008
- Refractory Epilepsy: Clinical OverviewEpilepsia, 2007
- The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy malesBritish Journal of Clinical Pharmacology, 2007
- Discovery of 4-Substituted Pyrrolidone Butanamides as New Agents with Significant Antiepileptic ActivityJournal of Medicinal Chemistry, 2003
- Measuring inconsistency in meta-analysesBMJ, 2003
- The anti‐epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA‐ and glycine‐gated currentsBritish Journal of Pharmacology, 2002
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996